Passage Bio Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Passage Bio Inc
TickerPASG
CIK #0001787297
CUSIP702712100
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
AddressTwo Commerce Square 2001 Market Street, 28th Floor, Philadelphia, PA 19103
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Passage Bio Inc 2019-09-06 110.0 M Exemption: 506(b), 3(c), 3(c)(1) · Remaining: $26 · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001787297] 10-K
[0001787297] 10-Q
[0001787297] 3
[0001787297] 4
[0001787297] 8-K
[0001787297] D
[0001787297] SC 13D
[0001787297] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Lynx1 Capital Management LP Passage Bio Inc [2026-07-02] 0.0
Baselake Partners LP Passage Bio Inc [2026-06-25] 0.0
Vestal Point Capital LP Passage Bio Inc [2024-11-14] 0.9
Erste Asset Management GmbH Passage Bio Inc [2024-11-14] 0.0
Lynx1 Capital Management LP Passage Bio Inc [2024-03-29] 8.7
Lynx1 Capital Management LP Passage Bio Inc [2022-09-29] 5.1
BlackRock Inc Passage Bio Inc [2022-07-08] 2.5
BlackRock Inc Passage Bio Inc [2022-02-04] 6.5
Deep Track Capital LP Passage Bio Inc [2021-10-25] 5.27
New Leaf Ventures III LP Passage Bio Inc [2021-02-11] 4.7
LAV Prescience Ltd Passage Bio Inc [2021-02-09] 5.3
FMR LLC Passage Bio Inc [2020-06-10] 0.0
Versant Venture Capital VI LP Passage Bio Inc [2020-03-13] 11.0
Access Industries Holdings LLC Passage Bio Inc [2020-03-12] 5.9
OrbiMed Advisors LLC Passage Bio Inc [2020-03-09] 13.5
Frazier Life Sciences IX LP Passage Bio Inc [2020-03-09] 10.9
Vivo Capital VIII LLC Passage Bio Inc [2020-03-06] 4.9
Form 3/4/5 Filer 2011 - 2026
Nichols Weston
Passage Bio Inc
Lynx1 Capital Management LP
Countouriotis Athena
Kapadia Sandip
Kassberg Thomas Richard
Porter Derrell
Gowen Maxine
Sondhi Dolan
Borthwick Kathleen
Chou William
OrbiMed Advisors LLC
OrbiMed Capital GP VII LLC
Islam Saqib
Cale Edgar B
Forman Mark S
King Simona
Fotopoulos Alexandros
Woiwode Thomas
Kamarck Michael E
Toernsen Monika Maria
Goldsmith Bruce A
Salinas Eliseo Oreste
Quigley Jill M
Burkavage Brian
Yamada Tadataka
Ratcliffe Liam
Morris Richard Steven
Romano Gary
Versant Vantage I LP
Versant Vantage I GP-GP LLC
Versant Ventures VI GP LP
Versant Vantage I GP LP
Versant Ventures VI GP-GP LLC
Versant Venture Capital VI LP
Frazier Life Sciences IX LP
Fhmls IX LLC
Topper James N
Fhmls IX LP
Heron Patrick J
Squinto Stephen P
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Borthwick Kathleen
Employee Stock Option (right to buy) · derivative
2026-03-16 Grant 15,610 $0.00
Chou William
Employee Stock Option (right to buy) · derivative
2026-03-16 Grant 58,000 $0.00
Chou William
Common Stock
2026-01-08 Sell 4,076 $18.44 75,161
Borthwick Kathleen
Common Stock
2026-01-08 Sell 2,062 $18.44 38,023
Chou William
Restricted Stock Unit · derivative
2026-01-08 Option exercise 10,000 $0.00
Chou William
Common Stock
2026-01-08 Option exercise 10,000
Borthwick Kathleen
Restricted Stock Unit · derivative
2026-01-08 Option exercise 5,000 $0.00
Borthwick Kathleen
Common Stock
2026-01-08 Option exercise 5,000
Common Stock
2025-09-15 Buy 11,900 $6.99 83,181
Common Stock
2025-09-12 Buy 19,783 $6.99 138,283
Common stock, $0.0001 par value per share (Common Stock)
2025-09-11 Buy 325 $6.96 2,262
Nichols Weston +1
Common Stock
2025-07-24 Buy 66,423 $5.71 379,275
Nichols Weston +1
Common Stock
2025-07-23 Buy 49,302 $5.74 282,993
Nichols Weston +1
"Common stock, $0.0001 par value per share (""Common Stock"")"
2025-07-22 Buy 13,123 $5.44 71,389
OrbiMed Advisors LLC +1
Common Stock
2025-06-26 Sell 213,257 $0.33 70,375
OrbiMed Advisors LLC +1
Common Stock
2025-06-25 Sell 138,800 $0.33 45,804
OrbiMed Advisors LLC +1
Common Stock
2025-06-24 Sell 231,600 $0.35 81,060
Gowen Maxine
Director Stock Option (right to buy) · derivative
2025-05-28 Grant 201,857 $0.00
Kapadia Sandip
Director Stock Option (right to buy) · derivative
2025-05-28 Grant 201,857 $0.00
Countouriotis Athena
Director Stock Option (right to buy) · derivative
2025-05-28 Grant 201,857 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2025-09-30 2 87,427
2025-06-30 41 35,095,792
2025-03-31 45 36,370,242
2024-12-31 48 37,640,901
2024-09-30 46 38,675,230
2024-06-30 46 40,286,539
2024-03-31 52 40,351,913
2023-12-31 53 32,775,517
2023-09-30 52 32,396,126
2023-06-30 57 33,315,153
2023-03-31 60 35,554,684
2022-12-31 69 37,341,517
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com